ESTRO 2024 - Abstract Book

S1012

Clinical - Gynaecology

ESTRO 2024

Subdistributional hazard ratios for distant metastasis for the afore defined dose groups, using a total dose of 0 80 mg/m² as a reference, were 0.893 (95% CI: 0.514-1.553, p=0.69) at 90-160 mg/m², 0.598 (95% CI: 0.353-1.013, p=0.056) at 170-200 mg/m², and 0.818 (95% CI: 0.465-1.438, p=0.48) at >200 mg/m² in the overall population and 1.664 (95% CI: 0.482-5.733, p=0.42) at 90-160 mg/m², 0.949 (95% CI: 0.279-3.232, p=0.93) at 170-200 mg/m², and 1.056 (95% CI: 0.265-4.202, p=0.94) at >200 mg/m² in the low-risk group. The respective results in the high-risk group with 0-80 mg/m² as a reference were 0.757 (95% CI: 0.404-1.418, p=0.38) at 90-160 mg/m², 0.519 (95% CI: 0.288-0.933, p=0.028) at 170-200 mg/m², and 0.69 (95% CI: 0.371-1.283, p=0.24) at >200 mg/m².

Conclusion:

The analysis suggests that in low-risk patients the risk of distant metastasis was low and seems not related to the dose of cisplatin. In contrast, in high-risk patients, the cumulative dose seems to impact distant metastasis with the lowest incidence at 170-200mg/m2. Beyond 200mg/m2 no further benefit was observed.

Keywords: Cervical cancer, concurrent chemotherapy

References:

1 Knoth J, Nout R, Mahantshetty U, et al.; Systemic recurrence after primary chemoradiation in cervical cancer patients – an EMBRACE analysis. ESTRO 2022 Abstract OC-0830, ESTRO 2022 abstract book p748-49.

919

Proffered Paper

Randomised trial of nurse-led sexual rehabilitation after radiotherapy for gynaecological cancers

Isabelle Suvaal 1 , Lisanne B. Hummel 1 , Jan-Willem M. Mens 2 , Charlotte C. Tuijnman-Raasveld 1 , Roula Tsonaka 3 , Laura A. Velema 4 , Henrike Westerveld 5 , Jeltsje Cnossen 6 , An Snyers 7 , Ina M. Jürgenliemk-Schulz 8 , Ludy C.H.W. Lutgens 9 , Jannet C. Beukema 10 , Dorien Haverkort 11 , Marlies E. Nowee 12 , Cor D. de Kroon 1 , Wilbert B. van den Hout 3 , Carien L. Creutzberg 4 , Lena E. van Doorn 2 , Moniek M. ter Kuile 1 1 Leiden University Medical Center, Department of Obstetrics and Gynaecology, Leiden, Netherlands. 2 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy, Rotterdam, Netherlands. 3 Leiden University Medical Center, Department of Biomedical Data Sciences, Leiden, Netherlands. 4 Leiden University Medical Center, Department of Radiation Oncology, Leiden, Netherlands. 5 Amsterdam UMC location University of Amsterdam, Department of Radiation Oncology, Amsterdam, Netherlands. 6 Catharina Hospital, Department of Radiation Oncology, Eindhoven, Netherlands. 7 Radboudumc, Department of Radiation Oncology, Nijmegen, Netherlands. 8 University Medical Center Utrecht, Department of Radiation Oncology, Utrecht, Netherlands. 9 Maastro, Department of Radiation Oncology, Maastricht, Netherlands. 10 University Medical Center Groningen, Department of Radiation Oncology, Groningen, Netherlands. 11 Radiotherapiegroep, Department of Radiation Oncology, Arnhem, Netherlands. 12 The Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam, Netherlands

Purpose/Objective: